This study is a retrospective analysis of the diagnostic accuracy of FDOPA PET with MRI fusion to FDOPA PET without MRI fusion. Clinical FDOPA PET scans obtained between 2000 and 2008 at the University of Wisconsin Hospital and Clinics were assessed using measures derived from regions of interest (ROI) generated with fused MRI (fused group) and again with ROIs derived solely from PET data (non-fused groups). The ROIs were used to calculate ratios (Striatum/Occipital cortex, Striatum/Cerebellum) pertinent to Parkinson's disease (PD) pathology. The clinical records were assessed for demographic data, follow-up length, and diagnosis. Receiver Operator Characteristics with area under the curve (AUC) measures were calculated and compared using confidence intervals and hypothesis testing. 27 patients had FDOPA PET with median clinical follow-up of 4 years. Of these, 17 patients had FDOPA PET with a fusible MR image. Seven of the 27 had a non-PD movement disorder. AUCs for the ratio measures ranged from 0.97-1.0 (fused), 0.73-0.83 (non-fused), and 0.63-0.82 (matched non-fused). The fused images had improved accuracy compared to the matched non-fused and all non-fused groups for the striatum to occipital group (p=0.04, p=0.03), while the striatum to cerebellum ratio had improvement over the non-fused all group (p=0.041). MR fusion to FDOPA PET improves the accuracy of at least some measures (Striatum/Occiput, Striatum/Cerebellum) in the diagnosis of PD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484423 | PMC |
Mol Psychiatry
December 2024
From the Clinical & Translational Neuroscience Branch, Intramural Research Program, National Institute of Mental Health, NIH, DHHS, Bethesda, MD, 20892, USA.
Dysfunction of dopamine systems has long been considered a hallmark of schizophrenia, and nearly all current first-line medication treatments block dopamine D receptors. However, approximately a quarter of patients will not adequately respond to these agents and are considered treatment-resistant. Whereas abnormally high striatal presynaptic dopamine synthesis capacity has been observed in people with schizophrenia, studies of treatment-resistant patients have not shown this pattern and have even found the opposite - i.
View Article and Find Full Text PDFJ Endocrinol Invest
December 2024
Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg University Hospitals, Strasbourg University, Strasbourg, France.
Purpose: To investigate the influence of germline succinate dehydrogenase (SDHx) pathogenic variants on 6-[F]-fluoro-3,4-dihydroxyphenylalanine (F-DOPA) Positron Emission Tomography (PET) radiomic signature of head and neck paragangliomas (HNPGLs).
Methods: Forty-seven patients (20 SDH pathogenic variants carriers) harboring 55 HNPGLs were retrospectively included. HNPGLs were delineated using Nestle adaptive threshold.
Radiol Imaging Cancer
January 2025
From the Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui District, 200032 Shanghai, China; and Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
Purpose To evaluate the diagnostic performance of gallium 68 (Ga)-DOTA-NaI3-octreotide (Ga-DOTANOC) and fluorine 18 (F)-fluoro-l-3,4-dihydroxyphenylalanine (F-FDOPA) PET/CT in detecting recurrent or metastatic paragangliomas. Materials and Methods This single-center retrospective study included patients with paragangliomas who underwent both Ga-DOTANOC PET/CT and F-FDOPA PET/CT between August 2021 and December 2023. The diagnostic performance of these two tracers in detecting recurrent or metastatic tumors was compared using several metrics, including sensitivity, negative predictive value, and accuracy.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
November 2024
Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Parkinsonism Relat Disord
January 2025
Turku PET Centre, University of Turku, Turku, Finland; Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland.
Objective: To investigate neuroinflammation in Parkinson's disease (PD) with [C]PBR28 positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers, and the relationship to dopaminergic functioning measured with 6-[F]-fluoro-L-dopa ([F]FDOPA) PET.
Methods: The clinical cohort consisted of 20 subjects with PD and 51 healthy controls (HC). All HC and 15 PD participants underwent [C]PBR28 High Resolution Research Tomograph (HRRT) PET for the quantitative assessment of cerebral binding to the translocator protein (TSPO), a neuroinflammation marker.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!